Related Experiment Video

Updated: May 3, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

18.1K

Major therapeutic developments and current challenges in advanced melanoma

R J Sullivan1, K T Flaherty

  • 1Massachusetts General Hospital Cancer Center, 55 Fruit Street, Yawkey 9E, Boston, MA, 02114, U.S.A.

The British Journal of Dermatology
|January 22, 2014
PubMed

Insights

Advances in understanding melanoma pathogenesis have led to new treatments. Biomarker identification aids therapy selection, with ongoing research into treatment sequencing and resistance mechanisms for improved patient outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Malignant melanoma incidence is increasing globally.
  • Traditional treatment options for advanced melanoma were limited.
  • Recent breakthroughs in molecular biology and immunology have enhanced understanding of melanoma pathogenesis.

Purpose of the Study:

  • To summarize recent advances in melanoma treatment.
  • To highlight the role of biomarkers in personalized therapy selection.
  • To discuss ongoing research into treatment sequencing and resistance mechanisms.

Main Methods:

  • Review of recent drug approvals for advanced melanoma.
  • Analysis of new therapeutic agents demonstrating durable responses.
  • Exploration of biomarker-driven patient stratification.
  • Investigation into treatment efficacy and resistance mechanisms.

Main Results:

  • Four new drugs approved for advanced melanoma in the past two years.
  • Two novel classes of agents show potential for durable responses in a subset of patients.
  • Biomarker identification enables molecular subgroup segregation for targeted therapy.
  • Preliminary studies on optimal therapy sequencing and resistance mechanisms are underway.

Conclusions:

  • Recent therapeutic advancements offer improved options for advanced melanoma.
  • Biomarker-guided therapy selection is crucial for patient management.
  • Further research into treatment combinations and resistance is expected to increase durable response rates.

More Related Videos

Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation05:33

Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation

Published on: September 6, 2024

2.1K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K